首页> 美国卫生研究院文献>Chinese Medical Journal >Efficacy and Safety Investigation of Kuntai Capsule for the Add-back Therapy of Gonadotropin Releasing Hormone Agonist Administration to Endometriosis Patients: A Randomized Double-blind Blank- and Tibolone-controlled Study
【2h】

Efficacy and Safety Investigation of Kuntai Capsule for the Add-back Therapy of Gonadotropin Releasing Hormone Agonist Administration to Endometriosis Patients: A Randomized Double-blind Blank- and Tibolone-controlled Study

机译:坤泰胶囊对子宫内膜异位症患者促性腺激素释放激素激动剂的回馈治疗的疗效和安全性研究:一项随机双盲空白和替勃龙对照研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background:As a Chinese Traditional Medicine product, Kuntai capsule could improve the peri-menopausal symptoms in postmenopausal women. But it is still not clear whether Kuntai capsule has a good effect on alleviating peri-menopausal symptoms induced by gonadotropin releasing hormone agonist (GnRH-a) treatment. The purpose of this study was to investigate the clinical effectiveness and safety of Kuntai capsule, on peri-menopausal symptoms in endometriosis (EMS) patients, with postoperative GnRH-a treatment.
机译:背景:坤泰胶囊作为中药产品,可改善绝经后妇女的围绝经期症状。但尚不清楚坤泰胶囊是否对缓解由促性腺激素释放激素激动剂(GnRH-a)引起的围绝经期症状有良好的作用。这项研究的目的是研究昆泰胶囊对子宫内膜异位症(EMS)患者绝经后症状的临床有效性和安全性,并进行术后GnRH-a治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号